Reta glucagon-like peptide-1 (GLP-1) receptor agonists represent a groundbreaking method to diabetes management. These innovative therapies work by mimicking the inherent actions of GLP-1, a hormone secreted by the gut in response to food. By triggering GLP-1 receptors in the pancreas, these compounds boost insulin secretion and reduce glucagon rel

The burgeoning landscape of emerging treatments for weight management has seen the rise of both retatrutide and tirzepatide, both dual mode agonists targeting the GLP-1 and GIP receptors. While sharing a comparable therapeutic goal – improving glycemic control and promoting substantial weight decrease – they exhibit intriguing contrasts in thei